Literature DB >> 20486203

Plasma osteopontin as a predictor of coronary artery disease: association with echocardiographic characteristics of atherosclerosis.

Hala Abdel-Hameed Abdel-Azeez1, Manar Al-Zaky.   

Abstract

Osteopontin (OPN), a bone-related protein, is present within the atherosclerotic plaques, most strikingly in calcified plaques. Valvular calcifications are accepted as a part of the spectrum of atherosclerosis and are associated with atherosclerotic calcification in the coronary arteries. The study aimed to evaluate the association of plasma OPN with the presence and extent of coronary stenosis, mitral annular calcification (MAC), and aortic valve sclerosis in stable angina patients. We studied 120 subjects who underwent coronary angiography because of ischemic chest pain. Coronary artery disease (CAD) was defined as > or = 50% stenosis in > or = 1 coronary artery. MAC and aortic valve sclerosis were detected by echocardiography. Lipid profile, high sensitive C-reactive protein (hsCRP), and OPN were measured in all studied subjects. Patients with CAD had increased plasma OPN when compared with those without CAD (P < 0.001). Plasma OPN levels were significantly positively correlated with atherogenic lipid profile, hsCRP, MAC grading, aortic valve sclerosis grading, and the number of stenosed coronary vessels in CAD patients. In multivariate analysis, OPN was an independent predictor of CAD (P = 0.01), MAC (P = 0.01), and aortic valve sclerosis (P = 0.04). In conclusion, OPN is an independent predictor of MAC and aortic valve sclerosis. Plasma OPN levels reflect the extent of coronary stenosis and can be used as a biomarker to identify patients with coronary atherosclerosis. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20486203      PMCID: PMC6647711          DOI: 10.1002/jcla.20378

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  30 in total

1.  Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association. Writing Group.

Authors:  L Wexler; B Brundage; J Crouse; R Detrano; V Fuster; J Maddahi; J Rumberger; W Stanford; R White; K Taubert
Journal:  Circulation       Date:  1996-09-01       Impact factor: 29.690

Review 2.  Atherosclerosis--an inflammatory disease.

Authors:  R Ross
Journal:  N Engl J Med       Date:  1999-01-14       Impact factor: 91.245

3.  Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study.

Authors:  B F Stewart; D Siscovick; B K Lind; J M Gardin; J S Gottdiener; V E Smith; D W Kitzman; C M Otto
Journal:  J Am Coll Cardiol       Date:  1997-03-01       Impact factor: 24.094

4.  Neutralizing antibodies directed against osteopontin inhibit rat carotid neointimal thickening after endothelial denudation.

Authors:  L Liaw; D M Lombardi; M M Almeida; S M Schwartz; D deBlois; C M Giachelli
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-01       Impact factor: 8.311

5.  Osteopontin is expressed in human aortic valvular lesions.

Authors:  K D O'Brien; J Kuusisto; D D Reichenbach; M Ferguson; C Giachelli; C E Alpers; C M Otto
Journal:  Circulation       Date:  1995-10-15       Impact factor: 29.690

6.  Associations of coronary artery calcification and carotid intima-media thickness with plasma concentrations of vascular calcification inhibitors in type 2 diabetic patients.

Authors:  Masami Ishiyama; Eiji Suzuki; Jun Katsuda; Hiroshi Murase; Yoshitaka Tajima; Yukio Horikawa; Shinobu Goto; Tamio Fujita; Jun Takeda
Journal:  Diabetes Res Clin Pract       Date:  2009-06-03       Impact factor: 5.602

7.  Osteopontin plays an important role in the development of medial thickening and neointimal formation.

Authors:  Kikuo Isoda; Kenichirou Nishikawa; Yashuhiro Kamezawa; Mikoto Yoshida; Masatoshi Kusuhara; Masao Moroi; Norihiro Tada; Fumitaka Ohsuzu
Journal:  Circ Res       Date:  2002-07-12       Impact factor: 17.367

Review 8.  Vascular calcification: mechanisms and clinical ramifications.

Authors:  Moeen Abedin; Yin Tintut; Linda L Demer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-05-20       Impact factor: 8.311

9.  Osteopontin overexpression is associated with arterial smooth muscle cell proliferation in vitro.

Authors:  A P Gadeau; M Campan; D Millet; T Candresse; C Desgranges
Journal:  Arterioscler Thromb       Date:  1993-01

10.  The association between cardiac calcification and coronary artery disease.

Authors:  Honggang Chu; Jinling Chen; Ruiqiang Guo
Journal:  Acta Cardiol       Date:  2009-08       Impact factor: 1.718

View more
  14 in total

1.  Osteopontin in Vascular Disease.

Authors:  Zoe Shin Yee Lok; Alicia N Lyle
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-04       Impact factor: 8.311

2.  Plasmatic osteopontin and vascular access dysfunction in hemodialysis patients: a cross-sectional, case-control study (The OSMOSIS Study).

Authors:  Julie Contenti; Matthieu Durand; Sandor Vido; Serge Declemy; Juliette Raffort; Joseph Carboni; Sophie Bonnet; Christophe Koelsch; Réda Hassen-Khodja; Philippe Gual; Nathalie M Mazure; Nirvana Sadaghianloo
Journal:  J Nephrol       Date:  2021-09-01       Impact factor: 3.902

3.  Levels of miR-130b-5p in peripheral blood are associated with severity of coronary artery disease.

Authors:  Neslihan Coban; Aybike Sena Ozuynuk; Aycan Fahri Erkan; Filiz Guclu-Geyik; Berkay Ekici
Journal:  Mol Biol Rep       Date:  2021-10-23       Impact factor: 2.316

4.  Physical inactivity increases endostatin and osteopontin in patients with coronary artery disease.

Authors:  Michael Sponder; Monika Fritzer-Szekeres; Rodrig Marculescu; Brigitte Litschauer; Jeanette Strametz-Juranek
Journal:  Heart Vessels       Date:  2015-12-11       Impact factor: 2.037

5.  Serum levels of fetuin-A, osteoprotegerin and osteopontin in patients with coronary artery disease: effects of statin (HMGCoA-reductase inhibitor) therapy.

Authors:  Nikolaos P E Kadoglou; George Kottas; Stylianos Lampropoulos; Ioulia Vitta; Christos D Liapis
Journal:  Clin Drug Investig       Date:  2014-03       Impact factor: 2.859

6.  Glucose-Dependent Insulinotropic Peptide in the High-Normal Range Is Associated With Increased Carotid Intima-Media Thickness.

Authors:  Amra Jujić; Peter M Nilsson; Naeimeh Atabaki-Pasdar; Anna Dieden; Tiinamaija Tuomi; Paul W Franks; Jens Juul Holst; Signe Sørensen Torekov; Susana Ravassa; Javier Díez; Margaretha Persson; Emma Ahlqvist; Olle Melander; Maria F Gomez; Leif Groop; Martin Magnusson
Journal:  Diabetes Care       Date:  2020-11-18       Impact factor: 19.112

7.  Serum protein profiles predict coronary artery disease in symptomatic patients referred for coronary angiography.

Authors:  William A LaFramboise; Rajiv Dhir; Lori A Kelly; Patricia Petrosko; John M Krill-Burger; Christin M Sciulli; Maureen A Lyons-Weiler; Uma R Chandran; Aleksey Lomakin; Robert V Masterson; Oscar C Marroquin; Suresh R Mulukutla; Dennis M McNamara
Journal:  BMC Med       Date:  2012-12-05       Impact factor: 8.775

8.  Immunomodulation Induced by Stem Cell Mobilization and Harvesting in Healthy Donors: Increased Systemic Osteopontin Levels after Treatment with Granulocyte Colony-Stimulating Factor.

Authors:  Guro Kristin Melve; Elisabeth Ersvaer; Çiğdem Akalın Akkök; Aymen Bushra Ahmed; Einar K Kristoffersen; Tor Hervig; Øystein Bruserud
Journal:  Int J Mol Sci       Date:  2016-07-19       Impact factor: 5.923

9.  Plasma Osteopontin Levels and Adverse Cardiovascular Outcomes in the PEACE Trial.

Authors:  Ahmed D Abdalrhim; Tariq S Marroush; Erin E Austin; Bernard J Gersh; Nusret Solak; Syed A Rizvi; Kent R Bailey; Iftikhar J Kullo
Journal:  PLoS One       Date:  2016-06-10       Impact factor: 3.240

10.  Osteopontin is elevated in patients with mitral annulus calcification independent from classic cardiovascular risk factors.

Authors:  Michael Sponder; Christian Reuter; Monika Fritzer-Szekeres; Brigitte Litschauer; Thomas Binder; Jeanette Strametz-Juranek
Journal:  BMC Cardiovasc Disord       Date:  2016-06-10       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.